Stock Symbol INO - Inovio Pharmaceuticals Business Overview

Inovio Pharmaceuticals, the company behind the stock symbol INO, is a biotechnology firm that specializes in developing DNA-based immunotherapies for various diseases.

Their focus is on creating treatments that stimulate the body's natural defenses to fight specific health conditions.

Inovio's approach to vaccine development involves using a technology called electroporation, which helps deliver genetic material into cells more efficiently.

This method has shown promise in the development of vaccines for diseases such as COVID-19, Ebola, and HIV.

INOVIO reported a significant decrease in total revenue from $867,000 in Q3 2019 to $236,000 in Q3 2020.

The company's net income improved dramatically, reaching $19.2 million, largely due to a one-time gain from the revaluation of convertible bonds and an investment sale.

R&D expenses increased to $26.5 million in Q3 2020, mainly due to the company's focus on developing its COVID-19 vaccine, INO-4800.

INOVIO's COVID-19 vaccine, INO-4800, is currently under FDA review.

The company's financial results were announced after market close on November 9, 2020, with a conference call and webcast following at 4:30 p.m. ET.

INOVIO has invested heavily in its DNA Medicines Platform, with 15 clinical programs targeting various diseases, including HPV-associated diseases, cancer, and infectious diseases.

The company's innovative approach utilizes the CELLECTRA device for efficient delivery of DNA medicines, showing promise in clinical trials involving over 2,000 patients.

Additional reading: Stock Symbol B

The stock symbol ino is listed on the NASDAQ stock exchange. It's a well-established platform with a strong reputation.

INO is a biotech company focused on developing innovative medical treatments. Their research and development efforts have shown promising results in various areas of medicine.

Investors should note that INO's stock price can be volatile due to market fluctuations and the company's stage of development.

INOVIO will present at three investor conferences in September. Dr. Joseph Kim, President and CEO, will lead the sessions.

INOVIO's presentations will take place at H.C. Wainwright on September 14 at 9:30 a.m. ET, Cantor Global Healthcare on September 17 at 10:40 a.m. ET, and Oppenheimer on September 23 at 10:50 a.m. ET.

Discover more: M&t Bank Ticker Symbol

Inovio Pharmaceuticals has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5.

This rating is based on actual recommendations made by six brokerage firms.

The current ABR is the same as it was a month ago, at 2.00.

Strong Buy recommendations make up 50% of all recommendations.

This percentage has remained consistent over the past month.

Three out of six recommendations are Strong Buy, indicating a high level of confidence in the company.

The fact that the ABR has remained the same suggests stability in the brokerage community's opinion of Inovio Pharmaceuticals.

Stock Performance for Inovio Pharmaceuticals (INO) is quite volatile. The stock has seen a 6.63% increase in the last month, but over the past three months, it has dropped by 62.81%.

The 52-week high for INO is a notable $14.75, while the 52-week low is a concerning $1.74. This indicates a significant range in the stock's performance.

Here are the key performance metrics for INO:

The stock's beta of 0.84 indicates a relatively stable performance compared to the market. However, the 1 year and 3 year changes of -57.35% and -95.42% respectively, suggest a significant decline in the stock's value over time.

The company behind the stock symbol INO is Inovio Pharmaceuticals, a biotech firm known for its DNA-based immunotherapies.

Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania, and has a market capitalization of around $2.5 billion.

The company's shares are listed on the NASDAQ stock exchange under the ticker symbol INO.

INO stock has a high trading volume, with an average of over 1 million shares traded daily.

Inovio Pharmaceuticals has a diverse portfolio of products in various stages of development, including its lead candidate, INO-3100, for the treatment of HPV-related cancers.

The company has received funding from various sources, including the US government and private investors, to support its research and development efforts.

INO stock has experienced significant price fluctuations in recent years, with a high of over $14 per share in 2020 and a low of around $2.50 per share in 2022.

Intriguing read: Ars Pharmaceuticals Stock Symbol

As we dive into the world of stock symbols, it's worth noting that Ino (INO) is a relatively new player in the industry.

Ino's stock symbol is listed on the NYSE American exchange, which is a US-based stock exchange.

The company has a market capitalization of around $1.3 billion, making it a significant player in the industry.

Ino's stock price has been volatile, with a 52-week high of around $18.50 and a 52-week low of around $3.50.

The company's stock has shown significant growth potential, with a one-year return of around 300%.

For another approach, see: Ticker Symbol and Stock Exchange for Given Company Neximmune Inc

Thermo Fisher Scientific has partnered with INOVIO to manufacture INO-4800, INOVIO's DNA COVID-19 vaccine candidate.

This partnership will help scale up production to potentially 100 million doses in 2021, pending FDA approval.

Thermo Fisher will manage the drug substance manufacturing and filling processes, joining existing partners in INOVIO's global consortium.

INO-4800 has demonstrated excellent thermal stability and does not require freezing, which is crucial for global distribution.

The vaccine candidate is also preparing for Phase 2/3 trials, supported by $71 million in funding from the U.S. Department of Defense.

Readers also liked: Thermo Fisher Scientific Ticker Symbol

In the pharmaceuticals industry, competition is fierce.

Pfizer and Johnson & Johnson are two of the largest pharmaceutical companies in the world, with a combined market value of over $1 trillion.

Their strong brand recognition and wide range of products make them formidable competitors.

Novartis and Merck are also major players, with a significant presence in the global market.

Their research and development efforts have led to the creation of several innovative treatments.

Roche and GSK are also notable competitors, with a strong focus on research and development.

Their products cater to a wide range of health needs, from vaccines to cancer treatments.

Discover more: Johnson Controls Stock Symbol

In the pharmaceutical industry, companies like Inovio Pharmaceuticals have a history of releasing earnings reports and holding annual general meetings. The actual EPS for Inovio Pharmaceuticals' Q3 2024 Earnings Release was -0.890 USD.

These reports provide valuable insights into the company's financial performance. The Q2 2024 Earnings Release had an actual EPS of -1.190 USD.

Inovio Pharmaceuticals has also held annual general meetings, such as the one on 05/21/2024, which had an actual EPS of -6.090 USD. This meeting is an opportunity for shareholders to discuss the company's performance and future plans.

The company's earnings reports often show a decline in actual EPS over time. For example, the Q1 2024 Earnings Release had an actual EPS of -1.310 USD, compared to -1.050 USD in the Q4 2023 Earnings Release.

Here's a breakdown of some of Inovio Pharmaceuticals' past events:

These past events can give us a glimpse into Inovio Pharmaceuticals' financial performance and provide insight into the company's future prospects.